VT-1161 Emerges as Potential Treatment for Acute Vulvovaginal Candidiasis. Issue 48 (25th June 2015)

• Record Type: Journal Article
• Authors: Buckley, Rita
• Other Names: Brand Stephen R. presenter.
• Is Part Of: MD conference express. Volume 15:Issue 48(2015)
• Page Start: 19
• Page End: 19
• Publication Date: 2015-06-25
• Subjects: acute vulvovaginal candidiasis -- recurrent vulvovaginal candidiasis -- VT-1161 -- fungal infections -- yeast infection -- fluconazole -- infectious diseases clinical trials; Medicine -- Congresses; 610
• DOI: 10.1177/1559897715591486
• Languages: English
• ISSNs: 1559-8977

Abstract

The novel agent VT-1161 is safe and as effective as fluconazole for treating acute vulvovaginal candidiasis infections. Furthermore, it is more effective than fluconazole for preventing recurrent vulvovaginal candidiasis infections, particularly at its mid- and high doses, according to results from a phase 2 dose-ranging study. VT-1161 is now being evaluated in patients with recurrent vulvovaginal candidiasis in the REVIVE trial.